Tarceva® is the commercial brand name of Erlotinib Hydrochloride Tablets, an orally active reversible EGFR tyrosine kinase inhibitor developed by Roche. It selectively blocks epidermal growth factor receptor kinase to inhibit downstream tumor cell proliferation signaling. Main IndicationsFirst-line maintenance or…
Vizimpro® is the commercial brand name of Dacomitinib Tablets, an orally active irreversible pan-EGFR tyrosine kinase inhibitor developed by Pfizer. It irreversibly inhibits EGFR, HER2 and HER4 kinase activity to block downstream oncogenic signaling and suppress non-small cell lung cancer…
Giotrif® is the commercial brand name of Afatinib Dimaleate Tablets, an orally active irreversible EGFR/HER family tyrosine kinase inhibitor developed by Boehringer Ingelheim. It covalently binds to EGFR, HER2 and HER4 kinase domains to block downstream tumor proliferation signaling pathway.…
Lonsurf® is the commercial brand name of Trifluridine and Tipiracil Tablets, an orally active fixed-combination anticancer agent developed by Japan Taiho Pharmaceutical. Trifluridine inserts into tumor DNA to block cancer cell proliferation, and tipiracil inhibits trifluridine metabolic breakdown to sustain…
Livtencity® is the commercial brand name of Maribavir Tablets, an orally active anti-cytomegalovirus agent developed by Takeda Pharmaceutical. It inhibits CMV UL97 kinase to block viral DNA replication and virion maturation against drug-resistant cytomegalovirus. Main IndicationsTreatment of refractory or drug-resistant…
Dovato® is the commercial brand name of Lamivudine and Dolutegravir Sodium Tablets, an orally active dual-agent fixed-dose anti-HIV combination developed by ViiV Healthcare. Dolutegravir sodium inhibits HIV integrase to prevent viral DNA integration into host genome, while lamivudine blocks HIV…
Biktarvy® is the commercial brand name of Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets, an orally active single-tablet fixed-dose combination anti-HIV agent developed by Gilead Sciences. Bictegravir inhibits HIV integrase to block viral gene integration, while emtricitabine and tenofovir…
Epclusa® is the commercial brand name of Sofosbuvir and Velpatasvir Tablets, an oral fixed-dose combination anti-hepatitis C medicine developed by Gilead Sciences. Sofosbuvir inhibits HCV NS5B polymerase to block viral nucleic acid synthesis, while velpatasvir suppresses NS5A protein to hinder…
Harvoni® is the commercial brand name of Ledipasvir and Sofosbuvir Tablets, an oral fixed-dose combination anti-HCV drug developed by Gilead Sciences. Ledipasvir inhibits HCV NS5A protein while sofosbuvir blocks viral NS5B polymerase, jointly suppressing hepatitis C virus replication. Main IndicationsTreatment…
Ganovo® is the commercial brand name of Danoprevir Sodium Tablets, an orally active HCV NS3/4A protease inhibitor developed by Ascletis Pharma. It blocks hepatitis C virus protease to hinder viral protein cleavage and suppress HCV replication. Main IndicationsUsed in combination…